Previous 10 | Next 10 |
Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress The company's findings will be showcased to over 400 clinicians, respiratory health and critical care professionals, aerosol scientists, engineers, pr...
Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018) An estimated 3 to 10 million patients in the USA exhibit debilitating symptoms of Post-Acute Sequelae of SARS-CoV-2 PR Newswire ENGLEWOOD, Colo. , ...
Ampio Pharmaceuticals, Inc. (AMPE) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Dan Stokely - Chief Financial Officer Mike Macaluso - Chairman and Chief Executive Officer Dr. David Bar-Or - Director and Founder Holli Cherevka - Chief Operating Officer Conferenc...
Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Progress achieved across therapeutic platform, including in the AP-013 Phase III trial of Ampion™ in Osteoarthritis of the Knee (OAK) Initiated two Phase II trials ut...
Ampio Pharmaceuticals ([[AMPE]] +4.8%) has revealed positive results from its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress due to COVID-19.All patients in the study have now completed treatment, including a follow-up at Day 28 after treatment.The stu...
Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80% - All-cause mortality in patients treated using Standard of Care (SOC) was 24%, but only 5% in the group treated with Ampion (a 78% reduction) - The AP-014 Phase I trial of inhaled Ampi...
Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19 - Positive FDA response provides guidance on multiple pathways forward on paused Phase III trial in osteoarthritis of the knee (OAK) - Phase I trial of inhaled Ampio...
Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update PR Newswire ENGLEWOOD, Colo. , April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company foc...
Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects PR Newswire ENGLEWOOD, Colo. , April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company ...
Ampio Pharmaceuticals ([[AMPE]]) announces results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis, a condition that causes inflammation of the kidney.The aim of ...
News, Short Squeeze, Breakout and More Instantly...
Ampio Pharmaceuticals Inc. Company Name:
AMPE Stock Symbol:
OTCMKTS Market:
Ampio Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 94.4% to $0.07 on volume of 92,836,985 shares AGBA Group Holding Limited (AGBA) rose 46.1% to $1.505 on volume of 55,502,222 shares PROSHARES TRUST (SQQQ) rose 1.2% to $12.2099 on volume of 25,933,897 shares...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 7.2% to $0.04 on volume of 426,309,096 shares PROSHARES TRUST (SQQQ) rose 1.8% to $12.07 on volume of 171,048,374 shares AGBA Group Holding Limited (AGBA) rose 157.5% to $1.03 on volume of 121,894,6...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 73.2% to $0.0646 on volume of 191,555,690 shares AGBA Group Holding Limited (AGBA) rose 245.0% to $1.38 on volume of 41,065,125 shares TIAN RUIXIANG Holdings Ltd (TIRX) rose 135.2% to $1.14 on volum...